Anti-inflammatory drugs help reduce the risk of death for people hospitalized with Covid-19. New clinical trials show that many doctors have revived hope and debate about drugs that have been abandoned after the failure of previous clinical trials.
In a UK study of more than 4,000 inpatients, patients who received the rheumatoid arthritis drug tocilizumab plus steroids had a 20% risk of death after 28 days compared to patients who received steroids and standard treatment alone. It was shown to be low. Preliminary results Posted online this month.
The results have not yet been published in peer-reviewed scientific journals, but American scientists are paying attention to them because of the reputation of the Oxford University researchers who conducted the research. In June, researchers at the same Oxford University first proved the cheap and widely available steroid dexamethasone. Significant reduction The death of Covid-19, the discovery that the drug has become the standard treatment for most inpatients.
The researchers found that the Oxford study included far more patients with an average age of about 63 years, and only patients with high inflammation and hypooxygen measured in laboratory trials, so other studies. States that it may have succeeded if it fails. Make the drug more widely used, especially if the data is included as a recommended or recommended treatment in guidelines developed by influential organizations such as the National Institutes of Health and the Infectious Diseases Society of America. There is a possibility of becoming.
“So far, there have been many studies suggesting potential benefits, and others seemed less convincing,” said Francis Collins, director of the National Institutes of Health. I will. “I think what we were waiting for was a very large and well-designed study, and now I think it might be.”
Rheumatoid arthritis drug is promising in the fight against Covid-19
Source link Rheumatoid arthritis drug is promising in the fight against Covid-19